Literature DB >> 18922985

Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients.

Steven M Brunelli1, Katherine E Lynch, Elizabeth D Ankers, Marshall M Joffe, Wei Yang, Ravi I Thadhani, Harold I Feldman.   

Abstract

BACKGROUND AND OBJECTIVES: Evidence exists that variability in hemoglobin may be an independent risk factor for mortality among hemodialysis patients. These observations were based on a 1996 cohort, a time when anemia management differed greatly from present. Design, settings, participants and measurements: A retrospective cohort study of patients incident to Fresenius Medical Care units between 2004 and 2005 (n = 6644). Hemoglobin variability (Hgb-Var) was defined for each subject as the residual SD of a linear regression model of time on hemoglobin.
RESULTS: The mean (SD) of Hgb-Var was 1.13 (0.55) g/dl. In the primary analysis, each g/dl increase of Hgb-Var was associated with an adjusted hazard ratio (95% confidence interval) for all-cause mortality of 1.11 (0.92 to 1.33). No significant interaction with Hgb-Var and mortality was found on the basis of age (P = 0.22), arterial disease (P = 0.45), Hgb slope (P = 0.68), or mean Hgb (P = 0.78). When Hgb-Var was defined by a regression model that included a quadratic term for time (enabling descriptions of curvilinear hemoglobin trajectories), model fit was greatly improved (P for difference <0.001). The corresponding adjusted hazard ratio (95% confidence interval) for all-cause mortality was 1.17 (0.93 to 1.49).
CONCLUSIONS: Hgb-Var was not found to be associated with all-cause mortality when examined in a contemporary incident hemodialysis population. More research is needed to determine whether differences in these findings compared with prior analyses relate to temporal trends in anemia management or from differences in the relationship between Hgb-Var and outcomes among incident versus prevalent hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922985      PMCID: PMC2572293          DOI: 10.2215/CJN.02390508

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  19 in total

1.  Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients.

Authors:  L P McMahon; M J McKenna; T Sangkabutra; K Mason; S Sostaric; S L Skinner; C Burge; B Murphy; D Crankshaw
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

Review 2.  Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease.

Authors:  Madhumathi Rao; Brian J G Pereira
Journal:  Kidney Int       Date:  2005-10       Impact factor: 10.612

Review 3.  Anemia management in chronic kidney disease: what have we learned after 17 years?

Authors:  David M Spiegel
Journal:  Semin Dial       Date:  2006 Jul-Aug       Impact factor: 3.455

4.  Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology.

Authors:  Fuensanta Moreno; Dámaso Sanz-Guajardo; Juan Manuel López-Gómez; Rosa Jofre; Fernando Valderrábano
Journal:  J Am Soc Nephrol       Date:  2000-02       Impact factor: 10.121

5.  Hematocrit level and associated mortality in hemodialysis patients.

Authors:  J Z Ma; J Ebben; H Xia; A J Collins
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

6.  Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time.

Authors:  Bruce M Robinson; Marshall M Joffe; Jeffrey S Berns; Ronald L Pisoni; Friedrich K Port; Harold I Feldman
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

7.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.

Authors:  Steven Fishbane; Jeffrey S Berns
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

8.  History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.

Authors:  Steven M Brunelli; Marshall M Joffe; Rubeen K Israni; Wei Yang; Steven Fishbane; Jeffrey S Berns; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-12       Impact factor: 8.237

9.  Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients.

Authors:  Suying Li; Allan J Collins
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

10.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Ronald L Pisoni; Jennifer L Bragg-Gresham; Eric W Young; Tadao Akizawa; Yasushi Asano; Francesco Locatelli; Juergen Bommer; Jose Miguel Cruz; Peter G Kerr; David C Mendelssohn; Philip J Held; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2004-07       Impact factor: 8.860

View more
  16 in total

Review 1.  The elderly patients on hemodialysis.

Authors:  S Anand; M Kurella Tamura; G M Chertow
Journal:  Minerva Urol Nefrol       Date:  2010-03       Impact factor: 3.720

2.  Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients.

Authors:  Alexander Kainz; Bernd Mayer; Reinhard Kramar; Rainer Oberbauer
Journal:  Nephrol Dial Transplant       Date:  2010-05-26       Impact factor: 5.992

3.  The relation between hemoglobin variability and carotid intima-media thickness in chronic hemodialysis patients.

Authors:  Safa Ersen Ganidagli; Orcun Altunoren; Ertuğrul Erken; Ismet Onder Isık; Berivan Ganidagli; Necmi Eren; Yasemin Coskun Yavuz; Ozkan Gungor
Journal:  Int Urol Nephrol       Date:  2017-07-15       Impact factor: 2.370

Review 4.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Variability in measures of mineral metabolism in children on hemodialysis: impact on clinical decision-making.

Authors:  Aadil Kakajiwala; Thomas O Jemielita; Lawrence Copelovitch; Mary B Leonard; Susan L Furth; Amy York; Maryjane Benton; Andrew N Hoofnagle; Kimberly Windt; Karen Merrigan; April Lederman; Michelle R Denburg
Journal:  Pediatr Nephrol       Date:  2017-06-30       Impact factor: 3.714

6.  Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis.

Authors:  Keiichi Sumida; Charles Dyer Diskin; Miklos Z Molnar; Praveen K Potukuchi; Fridtjof Thomas; Jun Ling Lu; Connie M Rhee; Elani Streja; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Nephrol       Date:  2017-11-07       Impact factor: 3.754

7.  Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.

Authors:  Juan José Pérez-Ruixo; Mercedes Cucala-Ramos; Ester García-Gonzalo; Beatriz Del Val Romero; Neus Valveny
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

8.  Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.

Authors:  Adam E Gaweda; Linda J Goldsmith; Michael E Brier; George R Aronoff
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 8.237

9.  Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.

Authors:  Bulent Cetin; Barıs Afsar; Serpil Muge Deger; Ipek Isık Gonul; Ozge Gumusay; Ahmet Ozet; Mustafa Benekli; Ugur Coskun; Suleyman Buyukberber
Journal:  Int Urol Nephrol       Date:  2013-12-04       Impact factor: 2.370

10.  Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Authors:  Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.